DM001 for advanced solid tumors study
Part of Cancer, Lungs & breathing, Skin clinical trials.
This study tests an experimental drug called DM001 for people with certain advanced cancers (breast, lung, stomach, gastroesophageal, or colorectal) that have not responded to or are not helped by standard treatments. The goal is to see if the drug is safe and how it affects the tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have one of these advanced cancers that has spread: breast cancer, non-small cell lung cancer (NSCLC), stomach cancer, gastroesophageal cancer, or colorectal cancer.
- Standard treatment has stopped working, caused bad side effects, or is not available to you.
- You are at least 18 years old and able to make your own decisions about participating.
- You are in fairly good health (able to carry out light activities, like light housework or office work).
- You have a life expectancy of at least 3 months.
- You have at least one tumor that can be measured on scans.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called DM005 for people with advanced solid tumors (like lung, stomach, colon, liver, pancreas, or head and neck cancer) that have not responded to or can't tolerate standard treatments. The goal is to see if DM005 is safe and how well it works.
This trial tests a new drug called DM002 for people with advanced solid tumors that have not responded to standard treatments. The drug targets two proteins (MUC1 and HER3) found on some cancer cells, and may help shrink tumors or slow their growth.
This early-phase trial tests a new drug (CD-001) for people with advanced solid tumors. It will check if the drug is safe, how the body handles it, and if it helps shrink tumors.
This early-stage trial tests a new drug called IDP-001 in people with advanced cancers that have spread or cannot be surgically removed. The study aims to find the right dose and see how well the drug works against various solid tumors.
This trial tests a new drug, D3L-002, for people with advanced solid tumors that have stopped responding to at least one prior treatment or have no standard options. The goal is to see if it can help shrink or control the cancer.
This trial is testing an experimental drug called MR001 (a bispecific antibody) for people with advanced solid tumors that have not responded to other treatments. The goal is to see if it is safe and how well it works.
Hear when a new Breast Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.